Key result
Atorvastatin reduces HOMA index ~27% in PCOS, while simvastatin more effectively lowers total testosterone.
Why the study?
Does atorvastatin compared to simvastatin improve metabolic, endocrine, inflammatory, and oxidative profiles in women with polycystic ovary syndrome?
Population
64 women with polycystic ovary syndrome (PCOS)
Comparison
Atorvastatin 20 mg daily vs Simvastatin 20 mg daily
Design
RCT, randomized
Authors
Loading...
Clinicians may prioritize atorvastatin for insulin-resistant PCOS or simvastatin for hyperandrogenemia; extends RCT evidence for statin-specific effects.
RCT (n=64)
Randomized
Does atorvastatin compared to simvastatin improve metabolic, endocrine, inflammatory, and oxidative profiles in women with polycystic ovary syndrome?
Absolute Event Rate: -26.9% vs -8.3%
p-value: p=<0.01
Both atorvastatin and simvastatin improve inflammation and oxidative stress in PCOS, but atorvastatin has greater effects on insulin sensitivity while simvastatin more strongly affects hyperandrogenemia.
Kaya et al. (2010) conducted an RCT in Polycystic ovary syndrome (PCOS) (n=64). Atorvastatin vs. Simvastatin (20 mg daily) was evaluated on HOMA index reduction (p=<0.01). Atorvastatin significantly reduced HOMA index (-26.9%, P<0.01) and fasting insulin in women with PCOS, whereas simvastatin had a more dominant effect on total testosterone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: